Business
Gelteq Commences Veterinary Medicine Clinical Trial to Support an FDA Regulatory Pathway
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector. The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026. “This clinical trial represents a s
About this update from Gelteq Limited
[{"type":"image","alt":"Gelteq Limited","displaySize":"","headline":null,"caption":"Gelteq Limited","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":45,"url":"https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sKolMM.bRjvkyz9XOxielA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43","width":300,"height":45},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/sKolMM.bRjvkyz9XOxielA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/7b1e561b8eb101a1e67d96e6f6066b43","width":300,"height":45}},"lazy":false},{"type":"text","content":"MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq”) today announced the commencement of its first clinical trial for an antiparasitic drug candidate powered by Gelteq® technology, marking a significant milestone as the Company expands into the veterinary pharmaceutical sector.","length":306,"tagName":"p"},{"type":"text","content":"The clinical trial seeks to support Gelteq’s planned FDA regulatory pathway for animal use, with the Company targeting a potential application later in 2026.","length":157,"tagName":"p"},{"type":"text","content":"“This clinical trial represents a significant milestone for Gelteq as we expand into the veterinary pharmaceutical market,” said Nathan Givoni, CEO of Gelteq. “Building on our prior regulatory progress with the FDA, we are now advancing a key drug candidate powered by Gelteq® technology into the clinical stage as we work toward a potential regulatory submission in 2026. This step seeks to reinforce the versatility of Gelteq® technology and its potential across both human and animal health applications.”","length":508,"tagName":"p"},{"type":"text","content":"Advancing Toward FDA Applications","length":33,"tagName":"p"},{"type":"text","content":"Commencement of the clinical trial builds on Gelteq’s prior announcement regarding the FDA’s acceptance of its suitability petition, representing a key step in progressing the antiparasitic drug candidate powered by Gelteq® technology toward regulatory approval.","length":262,"tagName":"p"},{"type":"text","content":"The trial is expected to generate critical data to support the safety, efficacy, and formulation pe...